CONMED Company Insiders
CNMD Stock | USD 71.71 1.02 1.44% |
About 60% of all CONMED's insiders are taking a long position. The analysis of insiders' sentiment of trading CONMED stock suggests that some insiders are bullish at this time. CONMED employs about 4 K people. The company is managed by 31 executives with a total tenure of roughly 157 years, averaging almost 5.0 years of service per executive, having 129.03 employees per reported executive.
Curt Hartman Chairman Chairman of the Board, President, Chief Executive Officer |
Mark Tryniski Chairman Independent Chairman of the Board |
CONMED's Insider Buying Vs Selling
60
Selling | Buying |
Latest Trades
2024-06-14 | Stanley W Peters III | Disposed 4000 @ 71.82 | View | ||
2024-05-08 | Barbara J Schwarzentraub | Acquired 1442 @ 69.26 | View | ||
2024-05-06 | Martha Goldberg Aronson | Acquired 2000 @ 70.98 | View | ||
2024-04-30 | Pat Beyer | Acquired 3000 @ 68.3 | View | ||
2023-12-04 | Stanley W Peters III | Disposed 2300 @ 109.93 | View |
Monitoring CONMED's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
CONMED |
CONMED's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CONMED's future performance. Based on our forecasts, it is anticipated that CONMED will maintain a workforce of about 4000 employees by December 2024.CONMED Management Team Effectiveness
The company has return on total asset (ROA) of 0.0398 % which means that it generated a profit of $0.0398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1524 %, meaning that it created $0.1524 on every $100 dollars invested by stockholders. CONMED's management efficiency ratios could be used to measure how well CONMED manages its routine affairs as well as how well it operates its assets and liabilities. At present, CONMED's Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, CONMED's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 83.5 M, whereas Net Tangible Assets are projected to grow to (642.7 M).As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 25.9 M. The current year's Net Loss is expected to grow to about (68.9 M)
CONMED Workforce Comparison
CONMED is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 51,029. CONMED holds roughly 4,000 in number of employees claiming about 8% of equities under Health Care industry.
CONMED Profit Margins
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.42 | 0.5182 |
|
|
CONMED Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CONMED insiders, such as employees or executives, is commonly permitted as long as it does not rely on CONMED's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CONMED insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 1.5 | 3 | 2 | 60,727 | 54,303 |
2024-09-01 | 0.1667 | 2 | 12 | 1,500 | 31,406 |
2024-06-01 | 2.0 | 28 | 14 | 76,142 | 24,916 |
2024-03-01 | 2.6667 | 16 | 6 | 372,767 | 98,706 |
2023-12-01 | 0.5 | 2 | 4 | 3,500 | 7,000 |
2023-09-01 | 0.2 | 1 | 5 | 2,000 | 15,355 |
2023-06-01 | 0.7288 | 43 | 59 | 101,012 | 208,905 |
2023-03-01 | 1.0526 | 20 | 19 | 263,156 | 91,563 |
2022-12-01 | 0.4 | 2 | 5 | 4,524 | 14,500 |
2022-09-01 | 0.5 | 3 | 6 | 12,526 | 35,347 |
2022-06-01 | 1.4 | 28 | 20 | 39,943 | 30,455 |
2022-03-01 | 0.7 | 42 | 60 | 434,189 | 159,102 |
2021-12-01 | 0.3279 | 20 | 61 | 171,930 | 345,142 |
2021-09-01 | 0.5217 | 12 | 23 | 227,308 | 301,766 |
2021-06-01 | 0.9545 | 42 | 44 | 93,590 | 193,649 |
2021-03-01 | 0.6351 | 47 | 74 | 469,819 | 154,309 |
2020-12-01 | 0.375 | 27 | 72 | 240,952 | 511,607 |
2020-09-01 | 0.4444 | 4 | 9 | 9,635 | 26,260 |
2020-06-01 | 1.7222 | 31 | 18 | 87,278 | 99,095 |
2020-03-01 | 1.0882 | 37 | 34 | 729,583 | 168,416 |
2019-12-01 | 0.6471 | 11 | 17 | 55,306 | 106,897 |
2019-09-01 | 0.6071 | 17 | 28 | 64,978 | 123,324 |
2019-06-01 | 0.875 | 42 | 48 | 85,399 | 117,808 |
2019-03-01 | 0.9412 | 48 | 51 | 595,190 | 41,297 |
2018-12-01 | 2.0 | 8 | 4 | 2,408 | 1,554 |
2018-09-01 | 0.75 | 9 | 12 | 20,792 | 42,520 |
2018-06-01 | 0.8913 | 41 | 46 | 70,002 | 101,802 |
2018-03-01 | 0.8065 | 50 | 62 | 625,076 | 143,117 |
2017-12-01 | 0.5556 | 15 | 27 | 67,744 | 149,413 |
2017-09-01 | 1.0 | 1 | 1 | 157.00 | 3,000 |
2017-06-01 | 0.96 | 48 | 50 | 93,504 | 57,207 |
2017-03-01 | 1.0698 | 46 | 43 | 544,734 | 19,645 |
2016-12-01 | 0.4583 | 11 | 24 | 25,994 | 52,418 |
2016-09-01 | 1.0 | 2 | 2 | 398.00 | 8,135 |
2016-06-01 | 1.0 | 51 | 51 | 135,173 | 86,796 |
2016-03-01 | 1.1628 | 50 | 43 | 582,970 | 1,704,753 |
2015-12-01 | 1.1429 | 8 | 7 | 12,664 | 18,128 |
2015-09-01 | 2.6 | 13 | 5 | 16,577 | 2,500 |
2015-06-01 | 0.6789 | 74 | 109 | 106,096 | 94,003 |
2015-03-01 | 0.8421 | 32 | 38 | 470,979 | 163,862 |
2014-12-01 | 0.48 | 12 | 25 | 39,240 | 74,079 |
2014-09-01 | 0.7263 | 69 | 95 | 785,972 | 1,359,420 |
2014-06-01 | 0.7045 | 93 | 132 | 230,744 | 132,924 |
2013-12-01 | 0.4762 | 10 | 21 | 118,831 | 252,429 |
2013-09-01 | 1.0 | 22 | 22 | 90,434 | 140,851 |
2013-06-01 | 0.6623 | 151 | 228 | 465,614 | 319,811 |
2013-03-01 | 0.5882 | 20 | 34 | 263,949 | 463,084 |
2012-12-01 | 0.4615 | 6 | 13 | 25,403 | 59,034 |
2012-09-01 | 0.5385 | 7 | 13 | 50,779 | 124,481 |
2012-06-01 | 0.7619 | 80 | 105 | 318,575 | 305,406 |
2012-03-01 | 0.4643 | 13 | 28 | 166,798 | 331,768 |
2011-12-01 | 0.375 | 6 | 16 | 68,086 | 140,969 |
2011-06-01 | 0.785 | 84 | 107 | 389,662 | 416,932 |
2011-03-01 | 0.4167 | 5 | 12 | 35,250 | 103,427 |
2010-12-01 | 0.2 | 2 | 10 | 67,586 | 152,351 |
2010-06-01 | 0.9531 | 61 | 64 | 203,670 | 66,953 |
2010-03-01 | 0.6364 | 7 | 11 | 20,082 | 24,778 |
2009-12-01 | 0.6471 | 11 | 17 | 133,392 | 115,893 |
2009-06-01 | 1.02 | 51 | 50 | 197,521 | 44,728 |
2009-03-01 | 0.5556 | 5 | 9 | 4,663 | 21,300 |
2008-12-01 | 1.0 | 4 | 4 | 2,156 | 40,000 |
2008-09-01 | 0.2469 | 20 | 81 | 168,996 | 338,579 |
2008-06-01 | 1.4516 | 45 | 31 | 187,967 | 33,780 |
2008-03-01 | 0.025 | 1 | 40 | 256.00 | 110,000 |
2007-09-01 | 1.0 | 2 | 2 | 1,115 | 5,600 |
2007-06-01 | 0.488 | 61 | 125 | 853,641 | 167,276 |
2007-03-01 | 0.2143 | 9 | 42 | 53,066 | 185,222 |
2006-12-01 | 0.28 | 7 | 25 | 38,406 | 63,099 |
2006-09-01 | 0.5 | 1 | 2 | 25,000 | 40,000 |
2006-06-01 | 3.25 | 26 | 8 | 259,693 | 21,516 |
2006-03-01 | 5.0 | 5 | 1 | 3,886 | 3,004 |
2005-12-01 | 1.0 | 4 | 4 | 12,125 | 12,125 |
2005-09-01 | 0.1852 | 5 | 27 | 78,298 | 175,852 |
2005-06-01 | 0.1493 | 33 | 221 | 476,444 | 677,859 |
2005-03-01 | 0.1017 | 18 | 177 | 225,627 | 687,479 |
2004-12-01 | 0.2879 | 19 | 66 | 87,305 | 159,658 |
2004-09-01 | 0.5714 | 4 | 7 | 8,105 | 15,000 |
2004-06-01 | 1.8889 | 17 | 9 | 331,627 | 23,454 |
2004-03-01 | 0.9107 | 51 | 56 | 291,682 | 366,648 |
2003-12-01 | 0.2632 | 10 | 38 | 96,779 | 125,051 |
2003-09-01 | 0.2353 | 4 | 17 | 23,993 | 37,874 |
2003-06-01 | 3.0 | 3 | 1 | 0.00 | 1,200 |
CONMED Notable Stakeholders
A CONMED stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CONMED often face trade-offs trying to please all of them. CONMED's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CONMED's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Curt Hartman | Chairman of the Board, President, Chief Executive Officer | Profile | |
Mark Tryniski | Independent Chairman of the Board | Profile | |
Patrick Beyer | President of CONMED International | Profile | |
Todd Garner | Chief Financial Officer, Executive Vice President | Profile | |
David Murray | President Electrosurgery | Profile | |
Terence Berge | Vice President and Corporate Controller | Profile | |
Peter Shagory | Executive Vice President - Strategy and Corporate Development | Profile | |
Heather Cohen | Executive Vice President - Human Resources, Secretary | Profile | |
Stanley Peters | Vice President and General Manager - U.S. Advanced Surgical | Profile | |
Daniel Jonas | Executive Vice President - Legal Affairs, General Counsel, Secretary | Profile | |
Johonna Pelletier | Treasurer and Vice President - Tax | Profile | |
Stanley III | President Technologies | Profile | |
John Kennedy | Vice President and General Manager - U.S. Endoscopic Technologies | Profile | |
Todd CPA | CFO VP | Profile | |
John Workman | Independent Director | Profile | |
Charles Farkas | Independent Director | Profile | |
Jerome Lande | Independent Director | Profile | |
David Bronson | Independent Director | Profile | |
Brian Concannon | Independent Director | Profile | |
Martha Aronson | Lead Independent Director | Profile | |
Johonna CPA | VP Treasurer | Profile | |
John Ferrell | Executive Resources | Profile | |
Laverne Council | Independent Director | Profile | |
Shanna Cottiosmanski | Executive Vice President - Information Technology & CIO | Profile | |
Brent Lalomia | Executive Affairs | Profile | |
Barbara Schwarzentraub | Independent Director | Profile | |
Kimberly Lockwood | Interim Controller | Profile | |
Hollie Foust | General Secretary | Profile | |
Richard Glaze | Chief Officer | Profile | |
Sarah Oliker | Assistant General Counsel, Assistant Secretary | Profile | |
Daniel Esq | Special Secretary | Profile |
About CONMED Management Performance
The success or failure of an entity such as CONMED often depends on how effective the management is. CONMED management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CONMED management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CONMED management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.07 | |
Return On Capital Employed | 0.07 | 0.09 | |
Return On Assets | 0.03 | 0.04 | |
Return On Equity | 0.08 | 0.07 |
Please note, the presentation of CONMED's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CONMED's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CONMED's management manipulating its earnings.
CONMED Workforce Analysis
Traditionally, organizations such as CONMED use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CONMED within its industry.CONMED Manpower Efficiency
Return on CONMED Manpower
Revenue Per Employee | 310.2K | |
Revenue Per Executive | 40M | |
Net Income Per Employee | 16.1K | |
Net Income Per Executive | 2.1M | |
Working Capital Per Employee | 76.2K | |
Working Capital Per Executive | 9.8M |
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |